Prof. Dr. med. Marc Donath

Bazile, Cassandra, Abdel Malik, Magdy M., Ackeifi, Courtney, Anderson, Randy L., Beck, Roy W., Donath, Marc Y., Dutta, Sanjoy, Hedrick, Joseph A., Karpen, Stephen R., Kay, Thomas W. H., Marder, Thomas, Marinac, Marjana, McVean, Jennifer, Meyer, Robert, Pettus, Jeremy, Quattrin, Teresa, Verstegen, Ruud H. J., Vieth, Joshua A., & Latres, Esther. (2024). TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial [Journal-article]. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1470677

Hofwimmer, Kaisa, de Paula Souza, Joyce, Subramanian, Narmadha, Vujičić, Milica, Rachid, Leila, Méreau, Hélène, Zhao, Cheng, Dror, Erez, Barreby, Emelie, Björkström, Niklas K., Wernstedt Asterholm, Ingrid, Böni-Schnetzler, Marianne, Meier, Daniel T., Donath, Marc Y., & Laurencikiene, Jurga. (2024). IL-1β promotes adipogenesis by directly targeting adipocyte precursors [Journal-article]. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51938-x

Wälchli-Popovic, Milica, Monnerat, Sophie, Taylor, Angela E., Gilligan, Lorna C., Schiffer, Lina, Arlt, Wiebke, Vogt, Deborah R., De Geyter, Christian, Hutter, Nina, Donath, Marc Y., Sartorius, Gideon, & Christ-Crain, Mirjam. (2024). Effects of interleukin-1 receptor antagonism in women with polycystic ovary syndrome—the FertIL trial [Journal-article]. Frontiers in Endocrinology, 15. https://doi.org/10.3389/fendo.2024.1435698

Burak, Mehmet Furkan, Stanley, Takara L, Lawson, Elizabeth A, Campbell, Sophia L, Lynch, Lydia, Hasty, Alyssa H, Domingos, Ana I, Dixit, Vishwa D, Hotamışlıgil, Gökhan S, Sheedy, Frederick J, Dixon, Anne E, Brinkley, Tina E, Hill, Joseph A, Donath, Marc Y, & Grinspoon, Steven K. (2024). Adiposity, immunity, and inflammation: interrelationships in health and disease: a report from 24th Annual Harvard Nutrition Obesity Symposium, June 2023 [Journal-article]. The American Journal of Clinical Nutrition, 120(1), 257–268. https://doi.org/10.1016/j.ajcnut.2024.04.029

Aubry, Yoann, Dosch, Michel, & Donath, Marc Y. (2024). Cardiac evaluation in amiodarone-induced thyroid dysfunction with suspected cardiac ischemia?: a case report and review of the literature [Journal-article]. Journal of Medical Case Reports, 18(1). https://doi.org/10.1186/s13256-024-04552-w

Steiger, Laura, Baumann, Zora, Keller, Lena, Böni-Schnetzler, Marianne, Donath, Marc Y., & Meier, Daniel T. (2023). Protocol for isolation and spectral flow cytometry analysis of immune cells from the murine exocrine and endocrine pancreas [Journal-article]. STAR Protocols, 4(4), 102664. https://doi.org/10.1016/j.xpro.2023.102664

Quansah, Dan Yedu, Horsch, Antje, Gilbert, Leah, Donath, Marc Y., & Puder, Jardena J. (2023). C-reactive protein during pregnancy and in the early postpartum predicts adverse metabolic health outcomes at 1 year postpartum in women with gestational diabetes. Cardiovascular Diabetology, 22(1). https://doi.org/10.1186/s12933-023-02034-9

Wirth, Fabian, Heitz, Fabrice D., Seeger, Christine, Combaluzier, Ioana, Breu, Karin, Denroche, Heather C., Thevenet, Julien, Osto, Melania, Arosio, Paolo, Kerr-Conte, Julie, Verchere, C. Bruce, Pattou, François, Lutz, Thomas A., Donath, Marc Y., Hock, Christoph, Nitsch, Roger M., & Grimm, Jan. (2023). A human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-41986-0

de Baat, A., Meier, D. T., Rachid, L., Fontana, A., Böni-Schnetzler, M., & Donath, M. Y. (2023). Cystine/glutamate antiporter System xc- deficiency impairs insulin secretion in mice. Diabetologia, 66(11), 2062–2074. https://doi.org/10.1007/s00125-023-05993-6

de Baat, Axel, Meier, Daniel T., Rachid, Leila, Fontana, Adriano, Böni-Schnetzler, Marianne, & Donath, Marc Y. (2023). Cystine/glutamate antiporter System xc- deficiency impairs insulin secretion in mice [Journal-article]. Diabetologia, 66(11), 2062–2074. https://doi.org/10.1007/s00125-023-05993-6

de Baat, A., Meier, D. T., Fontana, A., Böni-Schnetzler, M., & Donath, M. Y. (2023). Cystine/Glutamate antiporter system xcdeficiency impairs macrophage glutathione metabolism and cytokine production. PLoS ONE, 18(10 October). https://doi.org/10.1371/journal.pone.0291950

de Baat, Axel, Trinh, Beckey, Ellingsgaard, Helga, & Donath, Marc Y. (2023). Physiological role of cytokines in the regulation of mammalian metabolism. Trends in Immunology, 44(8), 613–627. https://doi.org/10.1016/j.it.2023.06.002

Ferreira, Antonio, Schönenberger, Katja A., Potoczna, Natascha, Vogt, Andreas, Gerber, Philipp A., Zehetner, Jörg, Giachino, Daniel, Nett, Philipp, Gawinecka, Joanna, Cossu, Luca, Fuster, Daniel G., Dalla Man, Chiara, Facchinetti, Andrea, Melmer, Andreas, Nakas, Christos T., Hepprich, Matthias, Donath, Marc Y., Herzig, David, & Bally, Lia. (2023). Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology and Therapeutics, 25(7), 467–475. https://doi.org/10.1089/dia.2023.0036

Komminoth, Mathis, Donath, Marc Y., Hepprich, Matthias, Schuetz, Philipp, Blum, Claudine A., Mueller, Beat, Reny, Jean-Luc, Gosselin, Pauline, Breville, Gautier, Brändle, Michael, Henzen, Christoph, Leuppi, Jörg D., Kistler, Andreas D., Thurnheer, Robert, Beuschlein, Felix, Rudofsky, Gottfried, Aeberli, Daniel, Villiger, Peter M., Böhm, Stephan, et al. (2023). Glucocorticoid withdrawal and glucocorticoidinduced adrenal insufficiency: Study protocol of the randomized controlled «TOASST” (Taper Or Abrupt Steroid STop) multicenter trial. PLoS ONE, 18(4 April). https://doi.org/10.1371/journal.pone.0281585

de Baat, A., Meier, D. T., Rachid, L., Fontana, A., Böni-Schnetzler, M., & Donath, M. Y. (2023, January 19). Cystine/glutamate antiporter system Xc^-deficiency impairs insulin secretion [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2023.01.19.524735

Daetwyler, Eveline, Zippelius, Alfred, Danioth, Simona, Donath, Marc Y., & Gut, Lara. (2023). Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1248919

Meier, Daniel T, Rachid, Leila, Wiedemann, Sophia J, Traub, Shuyang, Trimigliozzi, Kelly, Stawiski, Marc, Sauteur, Loïc, Winter, Denise V, Le Foll, Christelle, Brégère, Catherine, Guzman, Raphael, Odermatt, Alex, Böni-Schnetzler, Marianne, & Donath, Marc Y. (2022). Prohormone convertase 1/3 deficiency causes obesity due to impaired proinsulin processing. Nature Communications, 13(1), 4761. https://doi.org/10.1038/s41467-022-32509-4

Meier DT, Rachid L, Wiedemann SJ, Traub S, Trimigliozzi K, Stawiski M, Sauteur L, Winter DV, Le Foll C, Brégère C, Guzman R, Odermatt A, Böni-Schnetzler M, & Donath MY. (2022). Prohormone convertase 1/3 deficiency causes obesity due to impaired proinsulin processing. Nature Communications, 13(1), 4761. https://doi.org/10.1038/s41467-022-32509-4

Hepprich, Matthias, Mudry, Jonathan M., Gregoriano, Claudia, Jornayvaz, Francois R., Carballo, Sebastian, Wojtusciszyn, Anne, Bart, Pierre-Alexandre, Chiche, Jean-Daniel, Fischli, Stefan, Baumgartner, Thomas, Cavelti-Weder, Claudia, Braun, Dominique L., Günthard, Huldrych F., Beuschlein, Felix, Conen, Anna, West, Emily, Isenring, Egon, Zechmann, Stefan, Bucklar, Gabriela, et al. (2022). Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial. eClinicalMedicine, 53. https://doi.org/10.1016/j.eclinm.2022.101649

Donath MY. (2022). Type 1 diabetes: what is the role of autoimmunity in β cell death? Journal of Clinical Investigation, 132(20). https://doi.org/10.1172/JCI164460

Wiedemann SJ, Trimigliozzi K, Dror E, Meier DT, Molina-Tijeras JA, Rachid L, Le Foll C, Magnan C, Schulze F, Stawiski M, Häuselmann SP, Méreau H, Böni-Schnetzler M, & Donath MY. (2022). The cephalic phase of insulin release is modulated by IL-1β. Cell Metabolism, 34(7), 991–1003. https://doi.org/10.1016/j.cmet.2022.06.001

Rohm TV, Meier DT, Olefsky JM, & Donath MY. (2022). Inflammation in obesity, diabetes, and related disorders. Immunity, 55(1), 31–55. https://doi.org/10.1016/j.immuni.2021.12.013

Ebrahimi F., Urwyler S.A., Betz M.J., Christ E.R., Schuetz P., Mueller B., Donath M.Y., & Christ-Crain M. (2021). Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-87207-w

Böni-Schnetzler, Marianne, Méreau, Hélène, Rachid, Leila, Wiedemann, Sophia J., Schulze, Friederike, Trimigliozzi, Kelly, Meier, Daniel T., & Donath, Marc Y. (2021). IL-1beta promotes the age-associated decline of beta cell function. iScience, 24(11). https://doi.org/10.1016/j.isci.2021.103250

Zweck E., Hepprich M, & Donath M.Y. (2021). Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study. Obesity Surgery, 31(6), 2497–2502. https://doi.org/10.1007/s11695-021-05277-1

Schiavon M., Herzig D., Hepprich M, Donath M.Y., Bally L., & Dalla Man C. (2021). Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia. Frontiers in Endocrinology, 12. https://doi.org/10.3389/fendo.2021.611253

Hepprich M, Zillig D., Florian-Reynoso M.A., Donath M.Y., & Rudofsky G. (2021). Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Therapy, 12(3), 943–954. https://doi.org/10.1007/s13300-021-01016-y

Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, et al. (2021). Author Correction: A guiding map for inflammation. (Patent No. 2). 22(2), Article 2. https://doi.org/10.1038/s41590-020-00846-5

Donath MY. (2021). Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? Cell Metabolism, 33(1), 2–4. https://doi.org/10.1016/j.cmet.2020.11.015

Wueest S., Seelig E, Timper K, Lyngbaek M.P., Karstoft K., Donath M.Y., Ellingsgaard H., & Konrad D. (2021). Il-6 receptor blockade increases circulating adiponectin levels in people with obesity: An explanatory analysis. Metabolites, 11(2), 1–7. https://doi.org/10.3390/metabo11020079

Hepprich M, Donath MY, & Hemkens L.G. (2020). Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia. BMC Medical Research Methodology, 20(1), 290. https://doi.org/10.1186/s12874-020-01171-z

Wiedemann SJ, Rachid L, Illigens B, Böni-Schnetzler M, & Donath MY. (2020). Evidence for cephalic phase insulin release in humans: A systematic review and meta-analysis. Appetite, 155, 104792. https://doi.org/10.1016/j.appet.2020.104792

Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR, & SEMIRA collaborators. (2020). Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. The Lancet, 396(10246), 267–276. https://doi.org/10.1016/S0140-6736(20)30636-X

Urwyler SA, Ebrahimi F, Burkard T, Schuetz P, Poglitsch M, Mueller B, Donath MY, & Christ-Crain M. (2020). IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1-7]) and Decreases Blood Pressure in Obese Individuals. Hypertension, 75(6), 1455–1463. https://doi.org/10.1161/HYPERTENSIONAHA.119.13982

Hepprich M, Wiedemann SJ, Schelker BL, Trinh B, Stärkle A, Geigges M, Löliger J, Böni-Schnetzler M, Rudofsky G, & Donath MY. (2020). Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β. Cell Metabolism, 31(4), 699–709. https://doi.org/10.1016/j.cmet.2020.02.013

Brykczynska U, Geigges M, Wiedemann SJ, Dror E, Böni-Schnetzler M, Hess C, Donath MY, & Paro R. (2020). Distinct Transcriptional Responses across Tissue-Resident Macrophages to Short-Term and Long-Term Metabolic Challenge. Cell Reports, 30(5), 1627–1643. https://doi.org/10.1016/j.celrep.2020.01.005

Ellingsgaard H, Seelig E, Timper K, Coslovsky M., Soederlund L, Lyngbaek MP, Wewer Albrechtsen NJ, Schmidt-Trucksäss A, Hanssen H, Frey WO, Karstoft K, Pedersen BK, Böni-Schnetzler M, & Donath MY. (2020). GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia, 63(2), 362–373. https://doi.org/10.1007/s00125-019-05045-y

Popovic M, Ebrahimi F, Urwyler SA, Donath MY, & Christ-Crain M. (2020). The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome. Endocrine Connections, 9(7), 715–723. https://doi.org/10.1530/EC-20-0197

Schulze, Friederike, Wehner, Josua, Kratschmar, Denise V., Makshana, Valmir, Meier, Daniel T., Häuselmann, Stéphanie P., Dalmas, Elise, Thienel, Constanze, Dror, Erez, Wiedemann, Sophia J., Traub, Shuyang, Nordmann, Thierry M., Rachid, Leila, De Baat, Axel, Rohm, Theresa V., Zhao, Cheng, Odermatt, Alex, Böni-Schnetzler, Marianne, & Donath, Marc Y. (2020). Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes. Scientific Reports, 10(1), 3035. https://doi.org/10.1038/s41598-020-59701-0

Trinh B, Donath MY, & Läubli H. (2020). Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab. Diabetes Care 2019;42:e153-e154 (Patent No. 1). 43(1), Article 1. https://doi.org/10.2337/dci19-0058

Donath MY, Dinarello CA, & Mandrup-Poulsen T. (2019). Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews Immunology, 19(12), 734–746. https://doi.org/10.1038/s41577-019-0213-9

Donath MY. (2019). Designer cytokine for the treatment of diabetes. Nature Metabolism, 1(10), 933–934. https://doi.org/10.1038/s42255-019-0130-z

Trinh B, Donath MY, & Läubli H. (2019). Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab (Patent No. 9). 42(9), Article 9. https://doi.org/10.2337/dc19-0908

Donath MY. (2019). Inflammation and type 2 diabetes: from basic science to treatment (Patent No. 4). 41(4), Article 4. https://doi.org/10.1007/s00281-019-00749-0

Donath MY, Meier DT, & Böni-Schnetzler M. (2019). Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. Endocrine Reviews, 40(4), 1080–1091. https://doi.org/10.1210/er.2019-00002

Ebrahimi, Fahim, Urwyler, Sandrine A., Schuetz, Philipp, Mueller, Beat, Bernasconi, Luca, Neyer, Peter, Donath, Marc Y., & Christ-Crain, Mirjam. (2019). Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial. Endocrine Connections, 8(6), 701–708. https://doi.org/10.1530/ec-19-0201

Popovic, Milica, Timper, Katharina, Seelig, Eleonora, Nordmann, Thierry, Erlanger, Tobias E., Donath, Marc Y., & Christ-Crain, Mirjam. (2019). Exercise upregulates copeptin levels which is not regulated by interleukin-1. PloS One, 14(5), e0217800. https://doi.org/10.1371/journal.pone.0217800

Seelig, Eleonora, Trinh, Beckey, Hanssen, Henner, Schmid-Trucksäss, Arno, Ellingsgaard, Helga, Christ-Crain, Mirjam, & Donath, Marc Y. (2019). Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes-A randomised open-label study. Endocrinology, Diabetes & Metabolism, 2(3), e00075. https://doi.org/10.1002/edm2.75

Trinh, Beckey, Hepprich, Matthias, Betz, Matthias J., Burkard, Thilo, Cavelti-Weder, Claudia, Seelig, Eleonora, Meienberg, Fabian, Kratschmar, Denise V., Beuschlein, Felix, Reincke, Martin, Odermatt, Alex, Hall, Michael N., Donath, Marc Y., & Swierczynska, Marta M. (2019). Treatment of Primary Aldosteronism with mTORC1 Inhibitors. The Journal of Clinical Endocrinology and Metabolism, 104(10), 4703–4714. https://doi.org/10.1210/jc.2019-00563

Ebrahimi F, Urwyler SA, Straumann S, Doerpfeld S, Bernasconi L, Neyer P, Schuetz P, Mueller B, Donath MY, & Christ-Crain M. (2018). IL-1 Antagonism in Men with Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 103(9), 3466–3476. https://doi.org/10.1210/jc.2018-00739

Lehrskov LL, Dorph E, Widmer AM, Hepprich M, Siegenthaler J, Timper K, & Donath MY. (2018). The role of IL-1 in postprandial fatigue. Molecular metabolism, 12, 107–112. https://doi.org/10.1016/j.molmet.2018.04.001

Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, & Ridker PM. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 71(21), 2392–2401. https://doi.org/10.1016/j.jacc.2018.03.002

Caduff A, Zanon M, Zakharov P, Mueller M, Talary M, Krebs A, Stahel WA, & Donath M. (2018). First Experiences With a Wearable Multisensor in an Outpatient Glucose Monitoring Study, Part I: The Users’ View. Journal of Diabetes Science and Technology, 12(3), 562–568. https://doi.org/10.1177/1932296817750932

Zanon M, Mueller M, Zakharov P, Talary MS, Donath M, Stahel WA, & Caduff A. (2018). First Experiences With a Wearable Multisensor Device in a Noninvasive Continuous Glucose Monitoring Study at Home, Part II: The Investigators’ View. Journal of Diabetes Science and Technology, 12(3), 554–561. https://doi.org/10.1177/1932296817740591

Böni-Schnetzler M, Häuselmann SP, Dalmas E, Meier DT, Thienel C, Traub S, Schulze F, Steiger L, Dror E, Martin P, Herrera PL, Gabay C, & Donath MY. (2018). β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion. Cell reports, 22(7), 1774–1786. https://doi.org/10.1016/j.celrep.2018.01.063

Swierczynska, Marta M., Betz, Matthias J., Colombi, Marco, Dazert, Eva, Jenö, Paul, Moes, Suzette, Pfaff, Cécile, Glatz, Katharina, Reincke, Martin, Beuschlein, Felix, Donath, Marc Y., & Hall, Michael N. (2018). Proteomic Landscape of Aldosterone-Producing Adenoma. Hypertension (Dallas, Tex. : 1979), 73(2), 469–480. https://doi.org/10.1161/hypertensionaha.118.11733

Wueest S, Laesser CI, Böni-Schnetzler M, Item F, Lucchini FC, Borsigova M, Müller W, Donath MY, & Konrad D. (2018). IL-6-type cytokine signaling in adipocytes induces intestinal GLP-1 secretion. Diabetes, 67(1), 36–45. https://doi.org/10.2337/db17-0637

Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, Böni-Schnetzler M, & Donath MY. (2017). The Role of Inflammation in β-cell Dedifferentiation. Scientific Reports, 7(1), 6285. https://doi.org/10.1038/s41598-017-06731-w

Dalmas E, Lehmann FM, Dror E, Wueest S, Thienel C, Borsigova M, Stawiski M, Traunecker E, Lucchini FC, Dapito DH, Kallert SM, Guigas B, Pattou F, Kerr-Conte J, Maechler P, Girard JP, Konrad D, Wolfrum C, Böni-Schnetzler M, et al. (2017). Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production. Immunity, 47(5), 928–942. https://doi.org/10.1016/j.immuni.2017.10.015

Ivovic A, Oprescu AI, Koulajian K, Mori Y, Eversley JA, Zhang L, Nino-Fong R, Lewis GF, Donath MY, Karin M, Wheeler MB, Ehses J, Volchuk A, Chan CB, & Giacca A. (2017). IKKβ inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents. Diabetologia, 60(10), 2021–2032. https://doi.org/10.1007/s00125-017-4345-9

Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, et al. (2017). A guiding map for inflammation. Nature Immunology, 18(8), 826–831. https://doi.org/10.1038/ni.3790

Kofler T, Yueksel F, Dirnhofer S, Donath MY, & Trendelenburg M. (2017). [Abdominal pain and hypertension in a 55-year-old male patient]. Der Internist, 58(4), 397–401. https://doi.org/10.1007/s00108-016-0170-3

Traub S, Meier DT, Schulze F, Dror E, Nordmann TM, Goetz N, Koch N, Dalmas E, Stawiski M, Makshana V, Thorel F, Herrera PL, Böni-Schnetzler M, & Donath MY. (2017). Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis. Cell Reports, 18(13), 3192–3203. https://doi.org/10.1016/j.celrep.2017.03.005

Dror E, Dalmas E, Meier DT, Wueest S, Thévenet J, Thienel C, Timper K, Nordmann TM, Traub S, Schulze F, Item F, Vallois D, Pattou F, Kerr-Conte J, Lavallard V, Berney T, Thorens B, Konrad D, Böni-Schnetzler M, & Donath MY. (2017). Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nature Immunology, 18(3), 283–292. https://doi.org/10.1038/ni.3659

Urwyler, Sandrine Andrea, Schuetz, Philipp, Ebrahimi, Fahim, Donath, Marc Y., & Christ-Crain, Mirjam. (2017). Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. The Journal of Clinical Endocrinology and Metabolism, 102(5), 1712–1718. https://doi.org/10.1210/jc.2016-3931

Bendik C.F., & Donath M.Y. (2016). Individualized treatment strategies for type 2 diabetes Individualisierte Behandlungsstrategien bei Diabetes mellitus Typ 2. Therapeutische Umschau, 73(6), 340–348. https://doi.org/10.1024/0040-5930/a000802

Cavelti-Weder, C., Timper, K., Seelig, E., Keller, C., Osranek, M., Lassing, U., Spohn, G., Maurer, P., Muller, P., Jennings, G. T., Willers, J., Saudan, P., Donath, M. Y., & Bachmann, M. F. (2016). Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. Molecular Therapy, 24(5), 1003–1012. https://doi.org/10.1038/mt.2015.227

Donath, Marc Y. (2016). Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia, 59(4), 679–682. https://doi.org/10.1007/s00125-016-3873-z

Donath, Marc Y. (2016). Behandlung von Typ-2-Diabetes: Praxisnahe Empfehlungen [Management of Type 2 Diabetes: a Practical Approach]. Praxis, 105(12), 699–702. https://doi.org/10.1024/1661-8157/a002368

Falconnier Bendik, Claudine, & Donath, Marc Y. (2016). Individualisierte Behandlungsstrategien bei Diabetes mellitus Typ 2. Therapeutische Umschau, 73(6), 340–348. https://doi.org/10.1024/0040-5930/a000802

Pollack, Rena M., Donath, Marc Y., LeRoith, Derek, & Leibowitz, Gil. (2016). Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. Diabetes Care, 39 Suppl 2, S244–52. https://doi.org/10.2337/dcs15-3015

Seelig, Eleonora, Timper, Katharina, Falconnier, Claudine, Stoeckli, Rolf, Bilz, Stefan, Oram, Richard A., McDonald, Timothy James, & Donath, Marc Y. (2016). Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes & Metabolism, 42(6), 453–456. https://doi.org/10.1016/j.diabet.2016.08.005

Timper, K., Dalmas, E., Dror, E., Rutti, S., Thienel, C., Sauter, N. S., Bouzakri, K., Bedat, B., Pattou, F., Kerr-Conte, J., Boni-Schnetzler, M., & Donath, M. Y. (2016). Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells. Gastroenterology, 151(1), 165–179. https://doi.org/10.1053/j.gastro.2016.03.003

Ehses JA, & Donath MY. (2015). Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes (Patent No. 3). 58(3), Article 3. https://doi.org/10.1007/s00125-014-3482-7

Caduff, Andreas, Zanon, Mattia, Müller, Martin, Zakharov, Pavel, Feldman, Yuri, De Feo, Oscar, Donath, Marc, Stahel, Werner A., & Talary, Mark S. (2015). The Effect of a Global, Subject, and Device-Specific Model on a Noninvasive Glucose Monitoring Multisensor System. Journal of Diabetes Science and Technology, 9(4), 865–872. https://doi.org/10.1177/1932296815579459

Herder, C., Dalmas, E., Boni-Schnetzler, M., & Donath, M. Y. (2015). The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. Trends in Endocrinology and Metabolism, 26(10), 551–563. https://doi.org/10.1016/j.tem.2015.08.001

Herder, C., & Donath, M. Y. (2015). Interleukin-1 receptor antagonist: friend or foe to the heart? The Lancet Diabetes & Endocrinology, 3(4), 228–229. https://doi.org/10.1016/s2213-8587(15)00035-2

Nordmann, Thierry M., Seelig, Eleonara, Timper, Katharina, Cordes, Mareike, Coslovsky, Michael, Hanssen, Henner, Schmidt-Trucksäss, Arno, & Donath, Marc Y. (2015). Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study. PLoS ONE, 10(10), e0139662. https://doi.org/10.1371/journal.pone.0139662

Sauter, N. S., Thienel, C., Plutino, Y., Kampe, K., Dror, E., Traub, S., Timper, K., Bedat, B., Pattou, F., Kerr-Conte, J., Jehle, A. W., Boni-Schnetzler, M., & Donath, M. Y. (2015). Angiotensin II Induces Interleukin-1β-Mediated Islet Inflammation and β-Cell Dysfunction Independently of Vasoconstrictive Effects. Diabetes, 64(4), 1273–1283. https://doi.org/10.2337/db14-1282

Timper, K., Seelig, E., Tsakiris, D. A., & Donath, M. Y. (2015). Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 29(7), 955–960. https://doi.org/10.1016/j.jdiacomp.2015.05.019

Moran A., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Greenbaum C.J., Herold K.C., Marks J.B., Raskin P., Sanda S., Schatz D., Wherrett D., Wilson D.M., Krischer J.P., Skyler J.S., Pickersgill L., De Koning E., Ziegler A.-G., et al. (2014). Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicenter, randomized double-masked, placebo-controlled trials. Diabetes Technology and Therapeutics, 16(SUPPL. 1). https://doi.org/10.1089/dia.2014.1510

Dalmas, Elise, & Donath, Marc Y. (2014). A role for interleukin-22 in the alleviation of metabolic syndrome. Nat Med, 20(12), 1379–1381. https://doi.org/10.1038/nm.3748

Donath, Marc Y. (2014). Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews. Drug Discovery, 13(6), 465–476. https://doi.org/10.1038/nrd4275

Donath, Marc Y., Hess, Christoph, & Palmer, Ed. (2014). What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia, 57(4), 653–655. https://doi.org/10.1007/s00125-013-3153-0

Rutti, Sabine, Arous, Caroline, Schvartz, Domitille, Timper, Katharina, Sanchez, Jean-Charles, Dermitzakis, Emmanouil, Donath, Marc Y., Halban, Philippe A., & Bouzakri, Karim. (2014). Fractalkine (CX3CL1), a new factor protecting beta-cells against TNFalpha. Molecular Metabolism, 3(7), 731–741. https://doi.org/10.1016/j.molmet.2014.07.007

Wueest, Stephan, Item, Flurin, Boyle, Christina N., Jirkof, Paulin, Cesarovic, NNikola, Ellingsgaard, Helga, Böni-Schnetzler, Marianne, Timper, Katharina, Arras, Margarete, Donath, Marc Y., Lutz, Thomas A., Schoenle, Eugen J., & Konrad, Daniel. (2014). Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 306(11), R861–7. https://doi.org/10.1152/ajpregu.00533.2013

Donath M.Y. (2013). Type 2 diabetes and islet inflammation (Vol. 4, pp. 80–85). S. Karger AG. https://doi.org/10.1159/000346508

Biason-Lauber, Anna, Böni-Schnetzler, Marianne, Hubbard, Basil P, Bouzakri, Karim, Brunner, Andrea, Cavelti-Weder, Claudia, Keller, Cornelia, Meyer-Böni, Monika, Meier, Daniel T, Brorsson, Caroline, Timper, Katharina, Leibowitz, Gil, Patrignani, Andrea, Bruggmann, Remy, Boily, Gino, Zulewski, Henryk, Geier, Andreas, Cermak, Jennifer M, Elliott, Peter, et al. (2013). Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metabolism, 17(3), 448–455. https://doi.org/10.1016/j.cmet.2013.02.001

Boeni-Schnetzler, Marianne, & Donath, Marc Y. (2013). How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. British Journal of Clinical Pharmacology, 76(2), 263–268. https://doi.org/10.1111/j.1365-2125.2012.04297.x

Donath, Marc Y. (2013). When metabolism met immunology. Nature Immunology, 14(5), 421–422. https://doi.org/10.1038/ni.2591

Donath, Marc Y, & Burcelin, Rémy. (2013). GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care, 36 Suppl 2, S145–8. https://doi.org/10.2337/dcs13-2015

Donath, Marc Y, Dalmas, Élise, Sauter, Nadine S, & Böni-Schnetzler, Marianne. (2013). Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metabolism, 17(6), 860–872. https://doi.org/10.1016/j.cmet.2013.05.001

Donath, M Y. (2013). Targeting inflammation in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 15 Suppl 3, 193–196. https://doi.org/10.1111/dom.12172

Moran, Antoinette, Bundy, Brian, Becker, Dorothy J., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Greenbaum, Carla J., Herold, Kevan C., Marks, Jennifer B., Raskin, Philip, Sanda, Srinath, Schatz, Desmond, Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S., Pickersgill, Linda, de Koning, Eelco, Ziegler, Anette-G, et al. (2013). Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, 381(9881), 1905–1915. https://doi.org/10.1016/s0140-6736(13)60023-9

Tang, Christine, Naassan, Anthony E, Chamson-Reig, Astrid, Koulajian, Khajag, Goh, Tracy T, Yoon, Frederick, Oprescu, Andrei I, Ghanim, Husam, Lewis, Gary F, Dandona, Paresh, Donath, Marc Y, Ehses, Jan A, Arany, Edith, & Giacca, Adria. (2013). Susceptibility to fatty acid-induced beta-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between beta-cell lipotoxicity and islet inflammation. Endocrinology, 154(1), 89–101. https://doi.org/10.1210/en.2012-1720

Timper, Katharina, Hruz, Petr, Beglinger, Christoph, & Donath, Marc Y. (2013). Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes Care, 36(7), e90–1. https://doi.org/10.2337/dc13-0199

Cavelti-Weder, Claudia, Babians-Brunner, Andrea, Keller, Cornelia, Stahel, Marc A, Kurz-Levin, Malaika, Zayed, Hany, Solinger, Alan M, Mandrup-Poulsen, Thomas, Dinarello, Charles A, & Donath, Marc Y. (2012). Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care, 35(8), 1654–1662. https://doi.org/10.2337/dc11-2219

Cavelti-Weder, Claudia, Muggli, Bettina, Keller, Cornelia, Babians-Brunner, Andrea, Biason-Lauber, Anna, Donath, Marc Y, & Schmid-Grendelmeier, Peter. (2012). Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care, 35(6), e41. https://doi.org/10.2337/dc12-0115

Erener, Süheda, Mirsaidi, Ali, Hesse, Mareike, Tiaden, André N, Ellingsgaard, Helga, Kostadinova, Radina, Donath, Marc Y, Richards, Peter J, & Hottiger, Michael O. (2012). ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation. The FASEB Journal, 26(6), 2631–2638. https://doi.org/10.1096/fj.11-200212

Levendal, R-A, Schumann, D, Donath, M, & Frost, C L. (2012). Cannabis exposure associated with weight reduction and beta-cell protection in an obese rat model. Phytomedicine, 19(7), 575–582. https://doi.org/10.1016/j.phymed.2012.02.001